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Objective. Chemotherapy-associated peripheral neuropathy (CAPN) is a painful side-eﬀect of chemotherapy. This study assesses
healthcare and workloss costs of CAPN patients with breast, ovarian, head/neck, or non-small cell lung cancer (NSCLC)
from a third-party payor/employer perspective. Research Design and Methods. Patients with qualifying tumors, and claims for
chemotherapy and services indicative of peripheral neuropathy (PN) within 9-months of chemotherapy (cases) were identiﬁed in
a administrative claims database. Cases were matched 1:1 to controls with no PN-related claims based on demographics, diabetes
history and propensity for having a diagnosis of PN during the study period (based on resource use and comorbidities in a 3-
month baseline period). Average all-cause healthcare costs, resource use and workloss burden were determined. Results.A v e r a g e
healthcare costs were $17,344 higher for CAPN cases than their non-CAPN controls, with outpatient costs being the highest
component (with cases having excess costs of $8,092). On average, each CAPN case had 12 more outpatient visits than controls,
and spent more days in the hospital. Workloss burden was higher for cases but not statistically diﬀerent from controls. Conclusion.
This study establishes that breast, ovarian, head/neck, or NSCLC patients with CAPN have signiﬁcant excess healthcare costs and
resource use.
1.Introduction
Chemotherapy-associated peripheral neuropathy (CAPN) is
an e u r o l o g i c a ls i d ee ﬀect of chemotherapy characterized by
loss of sensation in the hands and feet, burning or tingling
in limbs, and, in some cases, loss of hearing and blurred
vision. The neuropathic symptoms are progressive and tend
toincreaseaschemotherapytreatmentproceeds.Inaddition,
comorbid conditions may exacerbate the severity of CAPN
[1]. For example, diabetes can lead to peripheral neuropathy,
and diabetic patients with pre-existing nerve damage may be
predisposed to more severe forms of CAPN [2–4].
The chemotherapy drugs most commonly associated
withCAPNaretaxanes(paclitaxelanddocetaxel),vincaalka-
loids (vincristine and vinorelbine), and platinums (cisplatin,
carboplatin, and oxaliplatin). The incidence of CAPN varies
by drug and dose and can range across products from 4–
92% [1, 2, 5, 6]. For example, clinical trials of paclitaxel in
breast cancer list incidence rates for severe CAPN between
2–33%, with overall CAPN rates upwards of 60% [3, 7, 8].
Currently, there are no standard treatments to prevent or
mitigate CAPN, although several drug classes (e.g., tricyclic
antidepressants,antiepilepticdrugs,andadjuvantanalgesics)
have shown some activity in reducing neuropathic pain
[9, 10].
Few data exist regarding the health outcomes of CAPN
patients, CAPN’s eﬀects on chemotherapy treatment, and as-
sociatedcosts.However,Bergersuggestsneuropathiesingen-
eral can lead to adverse outcomes and higher costs [11]. In
particular, Berger found that patients with neuropathies had
healthcare costs triple those of controls; however, the study2 Chemotherapy Research and Practice
did not examine the costs associated with chemotherapy-
related neuropathies speciﬁcally [11].
Calhoun conducted a pilot study on the medical and
workloss costs associated with chemotherapy-induced tox-
icities in women with ovarian cancer [12]. Using survey
data on 42 patients suﬀering from chemotherapy-induced
neurotoxicities, the study found the medical costs directly
attributable to CAPN were $688 per episode but that indirect
costs (patient and caregiver workloss and paid caregiver
costs) were over $4,200 per episode. This pilot study relied
on patient recall of medical services used over 3-month
intervals. In addition, the sample was limited to women with
ovarian cancer and did not consider other cancer types.
To the authors’ knowledge, no study has quantiﬁed the
comprehensivehealthoutcomes,medicalcosts,andworkloss
burden of CAPN patients with breast, ovarian, head/neck,
or nonsmall cell lung cancer (NSCLC). The purpose of the
current study is to assess health outcomes as well as the
healthcare (i.e., medical and drug) and workloss cost burden
ofCAPNpatients(cases)inthese4tumortypesfromathird-
party payor/employer perspective. The ﬁrst objective is to
compare the healthcare costs of CAPN cases with those of
matched controls who have the same cancer but no CAPN.
The second objective is to compare workloss costs in patients
with and without CAPN. The third objective is to compare
the healthcare costs of CAPN cases and non-CAPN controls
who have comorbid diabetes. By examining these 4 tumor
types, this study captures the use of the chemotherapeutic
agents most commonly associated with CAPN.
2. Methods
2.1. Data. Data were obtained from a database of privately
insured administrative claims records (Ingenix Employer
Database) that included approximately 8 million beneﬁcia-
ries from 40 large US-based companies (1999–2006). The
companies have operations nationwide in a broad array of
industries and job classiﬁcations. The database contains de-
identiﬁed beneﬁciary information including demographics
(e.g., age and gender), enrollment, and medical and phar-
macy claims. Utilization measures include date of service,
diagnoses, procedures, and actual payments to providers.
Pharmaceutical drug claims include National Drug Code
(NDC), ﬁll date, days of supply, quantity, and actual
payments. In addition, disability claims and employee wage
information were available for employees in 23 companies.
2.2. Sample Selection. Three analytic samples consisting of
CAPN cases and matched non-CAPN controls were used
for this study. The main sample, consisting of cases and
controlswithoutdiabetes,wasusedtoevaluatethehealthcare
costs and resource use associated with CAPN patients. A
sample of cases and controls with diabetes was used in the
secondary analysis to evaluate the costs and resource use
associated with diabetic CAPN patients. Finally, a subsample
of employed cases and controls was used to assess the
workloss burden associated with CAPN patients. Table 1(a)
presents the sample selection.
2.2.1. Main CAPN Sample. Patients under age 65 were eli-
gible for inclusion in the main sample if they had at least 1
claim with a diagnosis for 1 or more of the following cancers
from 1999–2005: NSCLC, breast, ovarian, or head and neck.
The cancer types were identiﬁed using ICD-9-CM codes
(see Table 1(b)). To identify NSCLC from the overall lung
cancer sample, patients receiving chemotherapy regimens
characteristic of treatment for small cell lung cancer (SCLC)
were excluded. SCLC treatment was deﬁned in this study as
doublet therapy with a platinum agent in combination with
irinotecan, topotecan, or etoposide, or CCNU, melphalan,
and VP-16 CAV regimen chemotherapy treatments. Of the
patients with a claim for a qualifying tumor, only those with
a procedure code indicating chemotherapy administration
within 3 months of a claim for a qualifying tumor were
selected. The date of ﬁrst such chemotherapy administration
was considered the index date. To ensure that the index
event marked the start of a new line of chemotherapy for
the tumor, patients were required to have at least 3 months
of continuous eligibility prior to the index date with no
claims for chemotherapy. Since no speciﬁc diagnosis code
exists for CAPN, the authors developed an algorithm to
deﬁne peripheral neuropathy (PN) using ICD-9-CM codes
for related diagnoses and symptoms (see Table 1(b)). Any
PN deﬁned in the 9 months following the index date was
assumed to be CAPN. Thus, patients were classiﬁed as
CAPN if they had evidence of PN within 9 months of ﬁrst
chemotherapy treatment but had no evidence in the 3-
month baseline period. Finally, for this sample, patients with
evidence of diabetes (i.e., a diagnosis of 250.x) from at least
3 months up to 12 months prior to the index date or during
the 12 months following the index date were excluded.
2.2.2. Diabetic CAPN Sample. A sample of patients with 1
of the 4 tumor types, CAPN, and diabetes were selected for
the secondary analysis. The patient selection criteria were the
same as in the Main CAPN sample with the exception of the
diabetes criteria. Speciﬁcally, diabetic CAPN patients were
identiﬁed as those patients with a diagnosis of ICD-9-CM
code 250.x anytime from at least 3 months up to 1 year prior
totheindexdateorduringthe12monthsfollowingtheindex
date.
2.2.3.CAPNEmployeeSample. Asubsampleofpatientsfrom
the Main CAPN and Diabetic CAPN samples who were
employees with disability data were selected for the workloss
cost analysis. Note that this sample will not contain all
employed persons from the main and diabetic CAPN
samples but rather will only include the employees of the
subset of companies with disability data available.
2.2.4. Study Period for All Samples. The study period encom-
passed the 12 months following the index date. Since the
perspective adopted was that of the payor and the payor
incurs no cost for patients who withdraw from coverage,
no requirements were placed on the length of continuous
eligibility following the index event. The baseline period for
assessing patient history extended 3 months prior to the
index date except for ascertaining the presence of diabetes.Chemotherapy Research and Practice 3
Table 1: Inclusion criteria and ICD-9-CM codes used for analytic samples.
(a) Inclusion criteria
Criteria Number of patients
1 Number of beneﬁciaries under 65 at eligibility start 4,729,443
2 >1 breast, ovarian, head and neck, or nonsmall cell
lung cancer claim from 1999–2005
56,261
3
>1 chemotherapy treatment within 3 months following
a breast, ovarian, head and neck, or nonsmall cell lung
cancer diagnosis
14,142
4
>3 months of continuous eligibility prior to the ﬁrst
chemotherapy treatment for the qualifying tumor
during which no other chemotherapy treatment was
received
11,009
5 >1 diagnosis for peripheral neuropathy following ﬁrst
chemotherapy treatment
1,245
6 Peripheral neuropathy within 9 months of ﬁrst
chemotherapy treatment
525
Main CAPN sample: no diabetes history 454
Diabetic CAPN sample 71
Employee CAPN subsample 78
(b) ICD-9-CM Diagnosis Codes Used for Identiﬁcation of CAPN and Cancer
CAPN ICD-9-CM code
Polyneuropathy due to drugs 357.6
Disturbance of skin sensation 782.0
Inﬂammatory and toxic neuropathy 357.x
Toxic optic neuropathy 377.34
Reﬂex sympathetic dystrophy 337.2
Cervical root lesions 353.2
Lumbosacral root lesions 353.4
Other mononeuritis of unspeciﬁed site 355.7
Mononeuritis of unspeciﬁed site 355.9
Neuralgia, neuritis, or radiculitis 729.2
Brachial plexus lesions 353.0
Cancer ICD-9-CM code
Nonsmall cell lung cancer 162.x
Breast cancer 174.x, 175.x
Ovarian 183.x
Head and neck 195.0, 140.x, 141.x, 142.x, 143.x, 144.x, 145.x, 146.x, 147.x, 148.x,149.x
In all cases, the patients were required to have a minimum of
3 months eligibility prior to the index date to qualify for the
study.
2.3. Matching. Cases in the main CAPN sample and the
diabetes CAPN sample were separately matched to controls
selected from among the set of NSCLC, breast, ovarian,
and head/neck cancer patients receiving chemotherapy who
did not have a diagnosis for CAPN-related symptoms
at any time in the claims history and were under age
65. Controls were matched to cases based on age, gender,
employment status (employee versus nonemployee), cancer
type, index date of chemotherapy, length of followup
(controls were required to have postindex eligibility of
at least as long as their matched case), and the estimated
likelihood of developing CAPN. Each case was matched
1:1 to a control using an optimal matching algorithm [13].
Likelihood of developing CAPN was derived as a propensity
score from a logistic regression model based on resource
use and comorbidities during the baseline period. Specif-
ically, the model included age, sex, Charlson Comor-
bidity Index (CCI) [14], number of inpatient, primary
care, oncology, neurology, and other physician visits, and
binary variables indicating whether patient went to the4 Chemotherapy Research and Practice
emergency room or had depression or uncomplicated hyper-
tension.
The time period over which controls contributed to
the outcomes measures was truncated at the end of the
observation period for their matching case (i.e., the earlier of
either 12 months or when cases dropped from the database).
2.4. Measures. Healthcare costs were stratiﬁed into 3 mutu-
ally exclusive groups: chemotherapy costs, drug costs, and
medicalcosts.Costswerecomputedasthepaid(reimbursed)
amount by the insurer to the health-care provider and
were annualized to 2006 U.S. Dollars using the Consumer
Price Index for medical care. Chemotherapy costs included
medical claims with a chemotherapy procedure code and
pharmacy claims for oral chemotherapy agents, identiﬁed
by NDCs. Drug costs included all pharmaceutical claims
other than chemotherapy claims. Medical costs included
claims for inpatient, emergency department (ED), and
outpatient/other care. Costs included all claims associated
with any service provided to the case/control during the
study period regardless of diagnosis, procedure, or drug.
The subset of pharmaceutical and medical costs that could
be directly attributed to CAPN was estimated as follows:
CAPN-relateddrugcostsincludedthosefordrugspotentially
used for CAPN (i.e., amitriptyline, gabapentin, amifostine,
glutamine, tricyclic antidepressants, anti-epileptics, NSAIDs,
andopioids)andCAPN-relatedmedicalcostsincludedthose
from claims with a primary or secondary diagnosis of a
CAPN-related symptom (see Table 1(b)).
Healthcare resource use consisted of hospitalizations,
emergency department (ED), and outpatient/other services
(reported by type of visit). The resource use components
were deﬁned using provider specialty codes and/or place
of service codes on the claims. All claims during the study
period were included in assessing resource use, regardless
of the underlying reason for a visit. In addition, the pro-
portion of patients using CAPN-related drugs, and speciﬁc
chemotherapy agents were measured.
Workloss days and costs consisted of disability and med-
ically related absenteeism. Workloss costs during the 12-
month study period included actual employer payments
for disability days plus imputed costs for medically related
absenteeism. Medically related absenteeism costs were
imputed by multiplying the number of days with medical
services resource use by the employee’s wage: each hospi-
talization day accounted for a full day of workloss, and
outpatientvisitsaccountedforhalfadayofworkloss.Aswith
healthcare costs, total workloss costs were not limited to only
those related to a particular condition.
Patient characteristics included demographics, employ-
ment status (employee versus nonemployee), cancer type,
cancer stage (metastatic versus not metastatic), and comor-
bidities identiﬁed using claims during baseline period and
the 12-month study period. Metastatic cancer was deﬁned
usingclaimswithdiagnosesformetastases(ICD-9-CMcodes
196.0-199.1). The CCI was calculated from the claims data
and individual physical comorbidities included in the index
which were also identiﬁed [14].
2.5. Statistical Analyses. Baseline characteristics (demo-
graphics, comorbidities, resource use rates) were summa-
rized as proportions of the sample with the characteristic.
Continuous measures (e.g., healthcare costs, workloss costs,
resource use amount) were summarized by mean and stan-
dard deviation. Comparisons of matched pairs of categorical
variables used McNemar tests. Comparisons of the diﬀer-
ences in continuous measures between cases and controls
used paired t-tests. Excess costs of CAPN cases compared
with controls (i.e., costs of CAPN cases minus those of
controls) were compared between diabetic and nondiabetic
patients using a 2-sample t-test. All analyses were conducted
using SAS version 9.1 (SAS Institute Inc., Cary, NC). P-
values less than or equal to 0.05 were considered statistically
signiﬁcant.
3. Results
The main study sample for the healthcare cost and resource
use analysis contained 454 cases and controls without dia-
betes (see Table 1(a)). The diabetes sample for the secondary
analysis contained 71 diabetic cases and controls. The
employee subsample for the workloss cost and resource use
analysis contained 78 cases and controls.
3.1. Baseline Characteristics. Tables 2(A) and 3(A) show the
baseline comparison of CAPN cases and their matched non-
CAPN controls within the main sample. Cases and controls
were balanced in terms of types of cancer and CCI. However,
CAPN cases had more congestive heart failure (4% versus
2%, P = 0.0412) and uncomplicated hypertension (17%
versus 11%, P = 0.0164), whereas the control group had a
higher rate of complicated hypertension (3% versus 1%, P =
0.0290). Resource use was generally the same between cases
and controls; however, there were more cases with neurology
specialist visits than controls (5% versus 2%, P = 0.0482).
Thenumberofneurologyvisitsandneurologycostswerenot
signiﬁcantly diﬀerent.
3.2. Study Period Descriptive Characteristics, Healthcare Re-
source Use, and Costs. CAPN cases had signiﬁcantly higher
rates and counts of comorbidities and resource use dur-
ing the study period compared with matched non-CAPN
controls (Tables 4(A) and 5(A)). Signiﬁcantly more cases
had ﬁbromyalgia, obesity, and uncomplicated hypertension
during the study period than their matched controls. Cases
also had a higher CCI during the study period (4.7 versus
4.1, P<0.0001). There were no diﬀerences in the classes
of chemotherapy agents used by cases and controls. The
most common chemotherapeutic agents used by cases and
controls were taxanes (33%, 28%) and platinums (20%,
18%). Signiﬁcantly more cases used a CAPN-related drug
than controls (72% versus 56%, P<0.0001). Cases had
substantially higher rates and amounts of use of both in-
patient and outpatient visits during the study period. More
cases were hospitalized at least once compared with controls
(51% versus 37%, P<0.0001). CAPN cases had signiﬁcantly
higher rates and amounts of use for all outpatient compo-
nents except for primary care visits and lab/pathology. MoreChemotherapy Research and Practice 5
Table 2: Three-month baseline demographics and comorbidities of CAPN cases and non-CAPN controls.
(A) Main Sample: no diabetes (B) Diabetes Sample
Cases Controls P-value Cases Controls P-valuea
No. % No. % No. % No. %
N 454 454 71 71
Demographics
Age (mean, SD) 53.9 7.5 53.7 9.3 0.0006 58.5 5.0 57.9 8.3 0.5044
Gender (n, % male) 69 15% 69 15% 1.0000 13 18% 13 18% 1.0000
Employment Status (n, % employed) 75 17% 75 17% 1.0000 3 4% 3 4% 1.0000
Months followup (mean) 11.1 2.2 11.3 1.7
12-month followup 366 81% 56 79%
Time to CAPN (mean days, SD) 147.5 82.9 137.2 85.7
1–3 months 125 27% 22 31%
3–6 months 149 33% 26 37%
6–9 months 179 39% 23 33%
Cancer type
Nonsmall cell lung 82 18% 82 18% 1.000 18 25% 18 25% 1.000
Breast 316 70% 316 70% 1.000 42 59% 42 59% 1.000
Ovarian 28 6% 28 6% 1.000 7 10% 7 10% 1.000
Head and neck 27 6% 27 6% 1.000 4 6% 4 6% 1.000
Metastatic cancer 168 37% 164 36% 0.7883 33 46% 20 28% 0.0374
Comorbidities
Depressive disorders 23 5% 31 7% 0.2673 2 3% 3 4% 0.6547
Congestive heart failure 20 4% 10 2% 0.0412 7 10% 8 11% 0.7963
Fibromyalgia 7 2% 7 2% 1.0000 4 6% 1 1% 0.1797
Obesity 8 2% 2 0% 0.0578 2 3% 0 0% 0.0578
Hypertension—uncomplicated 76 17% 52 11% 0.0164 22 31% 24 34% 0.7316
Hypertension—complicated 4 1% 13 3% 0.0290 4 6% 0 0% 0.0290
Other cancers 83 18% 74 16% 0.4352 17 24% 21 30% 0.4497
Charlson Comorbidity Index 4.4 4.3 0.4913 6.0 4.5 0.0043
CAPN indicates chemotherapy-associated peripheral neuropathy; SD, standard deviation.
aP-values are determined using McNemar tests for proportions and paired t-tests for continuous measures.
cases saw a neurologist than did controls (29% versus 6%,
P<0.0001).
Table 6(A) shows the healthcare cost comparison for
cases and controls. For cases, mean annual per capita health-
care costs were $69,950 versus $52,606 per control, with an
excess annual per patient cost of $17,344 (P<0.0001). Mean
excess annual per patient healthcare costs for cases versus
controls were $36,660 for head and neck cancer, $18,790
for nonsmall cell lung cancer, $16,940 for breast cancer,
and $5,140 for ovarian and all were statistically signiﬁcant
(data not shown). Cases had signiﬁcantly higher component
costs compared with controls. Outpatient costs were the
highest component for both cases and controls. However,
theexcesscostsofoutpatientandinpatientcomponentswere
similar with cases having excess annual outpatient costs of
$8,092 per patient (P<0.0001) and excess annual inpatient
costs of $7,552 per patient (P<0.0001). Annual oncology-
related costs (i.e., chemotherapy and oncologist specialist
costs) were $22,453 for cases compared with $19,362 for
controls,withthemajorityofcostsbeingchemotherapycosts
($16,984 and $16,169 for cases and controls, resp., P =
0.5744). CAPN-related drug and medical costs accounted for
approximately 2% of total healthcare costs.
3.3. Workloss and Costs. There were no statistically signif-
icant diﬀerences in workloss measures between the subset
of 78 employees with CAPN and their matched non-CAPN
controls (Table 7). More cases had disability claims than
controls(35%versus26%,resp.).Casesalsohadalmosttwice
asmanydisabilitydaysastheirmatchedcontrols(37.4versus
20.4 days, resp.). While almost all cases and controls had at
least 1 medically related absenteeism day (95% and 97%,
resp.), cases missed 6 additional days over the 12-month
study period compared with controls.
A v e r a g ea n n u a lw o r k l o s sc o s t sw e r ea p p r o x i m a t e l y2 5 %
higher for cases than controls ($11,298 versus $9,043, resp.)
with a $2,255 annual per patient diﬀerence (Table 7). Cases
had both higher disability and higher medically-related
absenteeism costs than controls ($4,970 versus $3,356 for
disability and $6,329 versus $5,687 for medically-related
absenteeism). However, workloss cost diﬀerences were not
statistically signiﬁcant.6 Chemotherapy Research and Practice
Table 3: Three-month per-capita baseline resource use and healthcare costs of CAPN cases and non-CAPN controls.
(A) Main Sample: no diabetes (B) Diabetes Sample
Cases Controls P-valuea Cases Controls P-valuea
No. % No. % No. % No. %
N 454 454 71 71
Resource use rate
Hospitalizations 204 45% 193 43% 0.4692 43 61% 33 46% 0.1138
ED visits 75 17% 68 15% 0.5139 21 30% 16 23% 0.3980
Outpatient visits 444 98% 445 98% 0.8185 71 100% 70 99% 0.8185
Oncology 188 41% 174 38% 0.3408 26 37% 30 42% 0.4795
Neurology 22 5% 11 2% 0.0482 5 7% 1 1% 0.1025
Resource use amount Mean (SD) Mean (SD) P-valuea Mean (SD) Mean (SD) P-valuea
Hospitalizations 1.96 (5.53) 1.48 (3.21) 0.0956 3.48 (5.02) 4.10 (9.75) 0.5702
ED visits 0.24 (0.70) 0.21 (0.58) 0.3550 0.41 (0.73) 0.35 (0.76) 0.6310
Outpatient visits 11.37 (6.80) 11.25 (7.40) 0.7449 12.80 (6.08) 11.28 (6.76) 0.1420
Oncology 1.40 (3.06) 1.33 (3.47) 0.6673 1.38 (3.10) 1.44 (2.97) 0.9040
Neurology 0.06 (0.31) 0.03 (0.22) 0.0848 0.07 (0.26) 0.01 (0.12) 0.1029
Total costs $17,797 ($22,255) $17,180 ($25,240) 0.6698 $22,308 ($24,970) $21,061 ($22,748) 0.6898
Drug costs $433 ($857) $467 ($1,148) 0.6064 $800 ($868) $646 ($824) 0.2761
Medical costs $17,363 ($22,185) $16,712 ($25,140) 0.6527 $21,508 ($24,871) $20,415 ($22,636) 0.7268
Inpatient $6,496 ($19,301) $5,928 ($21,811) 0.6632 $11,220 ($22,256) $9,382 ($21,412) 0.4845
ED $127 ($826) $102 ($576) 0.6043 $125 ($290) $122 ($340) 0.9490
Outpatient $10,336 ($10,186) $10,328 ($10,282) 0.9900 $9,725 ($8,672) $10,358 ($9,840) 0.6935
Oncology $438 ($1,329) $439 ($1,796) 0.9841 $379 ($996) $431 ($1,452) 0.7989
Neurology $10 ($61) $9 ($108) 0.8812 $24 ($163) $1 ($7) 0.2435
CAPN indicates chemotherapy-associated peripheral neuropathy; SD, standard deviation; ED, emergency department.
aP-values are determined using McNemar tests for proportions and paired t-tests for continuous measures.
Table 4: Chemotherapy agents and comorbidities of CAPN cases and non-CAPN controls during the 12-month study period.
(A) Main Sample: no diabetes (B) Diabetes Sample
Cases Controls P-valuea Cases Controls P-valuea
N o .%N o .% N o .%N o .%
N 454 454 71 71
Metastatic cancer 171 38% 136 30% 0.0097 30 42% 22 31% 0.1306
Classes of select chemotherapy agents used
Taxanes 148 33% 125 28% 0.0978 30 42% 17 24% 0.0236
Vinca Alkaloids 18 4% 14 3% 0.4497 3 4% 2 3% 0.6547
Platinums 90 20% 80 18% 0.4014 17 24% 20 28% 0.5775
Comorbidities
Depressive disorders 68 15% 50 11% 0.0804 8 11% 3 4% 0.1317
Congestive heart failure 23 5% 20 4% 0.6219 12 17% 12 17% 1.0000
Fibromyalgia 37 8% 8 2% <.0001 8 11% 1 1% 0.0196
Obesity 9 2% 2 0% <.0001 1 1% 0 0% 0.2568
Hypertension—uncomplicated 114 25% 83 18% 0.0134 33 46% 35 49% 0.7576
Hypertension—complicated 13 3% 13 3% 1.0000 5 7% 1 1% 0.1025
Other cancersb 124 27% 101 22% 0.0838 20 28% 19 27% 0.8415
Charlson Comorbidity Index 4.7 4.1 <.0001 7.0 5.6 0.0052
CAPN indicates chemotherapy-associated peripheral neuropathy.
aP-values are determined using McNemar tests for proportions and paired t-tests for continuous measures.
bOther cancers include all cancers other than head and neck, breast, non-small cell lung, and ovarian.Chemotherapy Research and Practice 7
Table 5: Resource use of CAPN cases and non-CAPN controls during the 12-month study period.
(A) Main Sample: no diabetes (B) Diabetes Sample
Cases Controls P-valuea Cases Controls P-valuea
N o .%N o .% N o .%N o .%
N 454 454 71 71
Resource use rate
Medical
Hospitalizations 231 51% 166 37% <.0001 48 68% 32 45% 0.0136
ED visits 213 47% 170 37% 0.0037 42 59% 27 38% 0.0222
Outpatient visits 453 100% 447 98% 0.0339 71 100% 70 99% 0.0339
Oncology 288 63% 250 55% 0.0075 43 61% 39 55% 0.5050
Neurology 133 29% 29 6% <.0001 30 42% 5 7% <.0001
Primary care 354 78% 345 76% 0.4726 59 83% 60 85% 0.8185
Other physician 444 98% 428 94% 0.0035 71 100% 66 93% 0.0035
Lab/pathology 181 40% 160 35% 0.1540 21 30% 22 31% 0.8694
Other outpatient 400 88% 369 81% 0.0030 68 96% 61 86% 0.0522
Prescription drug use
At least 1 CAPN-related drug 329 72% 256 56% <.0001 66 93% 46 65% 0.0003
Resource use amount Mean (SD) Mean (SD) P-valuea Mean (SD) Mean (SD) P-valuea
Medical
Hospitalizations 5.6 (11.69) 3.2 (7.77) 0.0001 9.1 (14.38) 6.2 (13.44) 0.2195
ED visits 1.1 (2.80) 0.6 (1.28) 0.0022 1.6 (1.98) 0.8 (1.35) 0.0064
Outpatient visits 51.3 (29.57) 39.8 (26.81) <.0001 56.9 (27.02) 38.5 (25.10) <.0001
Oncology 12.7 (18.92) 9.2 (15.55) 0.0021 12.6 (16.97) 7.5 (10.62) 0.0322
Neurology 0.6 (1.29) 0.1 (0.51) <.0001 1.1 (1.87) 0.1 (0.56) 0.0002
Primary care 6.9 (12.65) 5.0 (8.74) 0.0085 7.4 (10.25) 5.7 (5.64) 0.2454
Other physician 22.1 (21.22) 17.2 (18.82) 0.0001 25.9 (20.63) 18.6 (18.82) 0.0217
Lab/pathology 1.1 (2.62) 0.9 (2.49) 0.2127 0.8 (3.59) 1.1 (3.93) 0.6594
Other outpatient 13.6 (16.47) 11.4 (15.97) 0.0349 15.5 (15.37) 11.0 (16.56) 0.0905
CAPN indicates chemotherapy-associated peripheral neuropathy; SD, standard deviation; ED, emergency department.
aP-values are determined using McNemar tests for proportions and paired t-tests for continuous measures.
3.4. Secondary Analysis of CAPN and Diabetes. Tables 2(B)
and 3(B) show the baseline comparison of diabetic cases and
their matched diabetic controls. Cases had more metastatic
disease (46% versus 28%, P = 0.0374), complicated hyper-
tension (6% versus 0%, P = 0.0290), and a higher CCI
than controls (6.0 versus 4.5, P = 0.0043). Resource use
was generally well balanced; however, cases did have more
primary care visits than controls (2.75 versus 1.75, P =
0.0136). There were no statistically signiﬁcant diﬀerences in
baseline costs.
Cases had signiﬁcantly higher rates and counts of re-
source use during the study period compared with controls
(see Tables 4(B) and 5(B)). More cases than controls used
taxanes (42% versus 24%, P = 0.0236). More cases were
hospitalized compared with controls (68% versus 45%, P =
0.0136) though the days per capita were not statistically
diﬀerent (9.1 versus 6.2 for cases and controls, resp., P =
0.2195). Six times as many cases had a neurology specialist
visit during the study period compared with controls (42%
versus 7%, P<0.0001). Cases also had 18.4 more outpatient
visits during the study period on average than the controls
(P<0.0001). CAPN-related drugs were used by 93% of cases
compared with 65% of controls (P = 0.0003).
For cases, annual per capita healthcare costs were
$76,555 versus $54,816 per control, with an excess annual
per patient cost of $21,739 (P = 0.0273, Table 6(B)). Annual
oncology-related costs were $25,181 for cases compared with
$15,377 for controls, with the majority of these costs being
chemotherapy costs ($20,990 and $13,033 for cases and con-
trols,resp.,P = 0.0670).Thediabeticcase’sannualpercapita
excess costs were higher than the control’s costs ($21,739
versus $17,344), however, this diﬀerence was not statistically
signiﬁcant.
4. Discussion
This study is the ﬁrst to use claims data to estimate the excess
costsofCAPNpatientsinbreast,nonsmallcelllung,ovarian,
and head and neck cancer over a matched sample of cancer
patientswithoutCAPN.Thisstudyalsoincludedasecondary
analysis to examine the excess costs of CAPN patients among
patients with comorbid diabetes.8 Chemotherapy Research and Practice
Table 6: Per capita healthcare costs for CAPN cases and non-CAPN controls during the 12-month study period.
(A) Main Sample: no diabetes (B) Diabetes Sample
Cases Controls P-valuea Cases Controls P-valuea
mean (SD) mean (SD) mean (SD) mean (SD)
N 454 454 71 71
Total healthcare costs $69,950 ($66,913) $52,606 ($55,554) <.0001 $76,555 ($63,379) $54,816 ($68,115) 0.0273
Chemotherapy costs $16,984 ($21,248) $16,169 ($27,055) 0.5744 $20,990 ($31,501) $13,033 ($19,725) 0.0670
Drug costs $3,744 ($5,333) $3,071 ($4,927) 0.0419 $6,017 ($7,461) $4,223 ($6,100) 0.1163
CAPN-related drugs $595 ($1,590) $328 ($1,041) 0.0016 $718 ($1,401) $371 ($782) 0.0832
Medical costs $49,223 ($56,500) $33,366 ($36,931) <.0001 $49,548 ($46,428) $37,561 ($57,723) 0.1614
Inpatient $14,050 ($35,793) $6,498 ($15,558) <.0001 $19,181 ($38,190) $15,148 ($44,098) 0.5637
ED $474 ($1,093) $263 ($730) 0.0005 $798 ($1,817) $243 ($535) 0.0172
Outpatient $34,698 ($36,712) $26,606 ($29,913) <.0001 $29,569 ($21,339) $22,170 ($29,244) 0.0921
Oncology $5,469 ($15,923) $3,193 ($8,478) 0.0072 $4,191 ($6,950) $2,344 ($4,729) 0.0554
Neurology $129 ($319) $46 ($433) 0.0011 $326 ($843) $44 ($278) 0.0103
Primary care $7,772 ($12,454) $6,543 ($9,920) 0.0979 $6,024 ($7,341) $4,472 ($5,965) 0.1252
Other physician $7,437 ($13,782) $6,804 ($17,452) 0.5247 $6,235 ($11,447) $5,150 ($16,025) 0.6502
Lab/pathology $414 ($1,825) $289 ($1,490) 0.2632 $485 ($2,027) $110 ($193) 0.1237
Other outpatient $13,476 ($24,509) $9,731 ($18,345) 0.0064 $12,307 ($16,297) $10,049 ($20,812) 0.4798
CAPN-related medical costs $725 ($2,005) $491 ($762)
CAPN indicates chemotherapy-associated peripheral neuropathy; SD, standard deviation; ED, emergency department.
aP-values are determined using McNemar tests for proportions and paired t-tests for continuous measures.
Table 7: Per capita workloss days and costs during the 12-month
study period.
Employee subsample
Cases Controls P-valuea
No. % No. %
N 78 78
Workloss rateb
Medically
related
absenteeism
74 95% 76 97% 0.4142
Disability 27 35% 20 26% 0.2367
Workloss days mean (SD) Mean (SD) P-valuea
Medically
related
absenteeism
31.5 (28.1) 25.3 (18.2) 0.0573
Disability 37.4 (75.4) 20.4 (50.8) 0.1048
Workloss costs mean (SD) mean (SD) P-valuea
Total employer
costs
$11,298 ($11,830) $9,043 ($12,416) 0.2161
Medically
related
absenteeism
$6,329 ($7,136) $5,687 ($6,200) 0.5012
Disability $4,970 ($10,994) $3,356 ($10,284) 0.3134
SD indicates standard deviation.
aP-values are determined using McNemar tests for proportions and paired
t-tests for continuous measures.
bWorkloss rate deﬁned as the number of people with ≥1 disability claim or
≥1 instance of medically-related absenteeism.
The results suggest that CAPN patients are associated
with a signiﬁcant and substantial economic burden among
the privately insured U.S. population. Cases with CAPN had
on average $17,344 higher healthcare costs during the 12-
month study period compared with controls without CAPN.
Compared with controls, more cases were hospitalized, had
an emergency department visit, saw an oncologist or neu-
rologist, and had other outpatient visits. In addition, each
casewithCAPNaveraged12moreoutpatientvisitsandspent
more days in the hospital. This suggests that in addition to
the excess cost burden to third-party payors, the patients
themselves may (depending on their insurance beneﬁts)
experience a large burden in terms of out-of-pocket costs
(e.g., copayments, coinsurance) and time spent on medical
care.
CAPN can lead to increased costs as a result of services
speciﬁcally aimed at mitigating the PN (e.g., increased physi-
cianvisitstomonitorthePN,costsofPNtreatment)andsec-
ondary eﬀects, such as switches in chemotherapy regimens
or exacerbated cancer. This study separately estimated the
costs for CAPN-related services and found they accounted
for less than 2% of healthcare costs during the 12-month
study period. While a signiﬁcantly higher proportion of
CAPN patients did use the pharmacologic treatments used
to manage neuropathic symptoms, these drugs are often
generic or lower cost relative to cancer treatments and
overall healthcare costs. CAPN-related medical costs were
low suggesting that the excess utilization demonstrated by
cases was not directly attributed to CAPN. However, the
CAPN-related costs as measured here may understate the
true burden related speciﬁcally to CAPN. First, because thereChemotherapy Research and Practice 9
are no speciﬁc diagnoses for CAPN, PN-related diagnoses
may be underreported on claims. In addition, the secondary
eﬀects of CAPN mentioned above are not included in the
CAPN-related subset of costs presented here but rather are
included in the chemotherapy, drug, and medical costs.
Overall, this study ﬁnds that patients with CAPN expe-
rience signiﬁcantly increased costs and resource use. It is
important not to conclude that all of the excess costs are
caused by CAPN. Since the cases and controls were matched
during the baseline period, the results suggest that CAPN
is a serious condition that should be carefully monitored
in clinical practice. Improvements to the diagnostic tools
for CAPN severity and investigation of therapies that treat
CAPN without negatively impacting the cancer treatment
could beneﬁt both patients and payors.
Calhoun’s pilot study of chemotherapy-induced toxicity
found that the direct CAPN costs for women with ovarian
cancer are $688 for episodes up to 9 months, compared with
our ﬁndings that CAPN-related costs are on average $1,320
over a period up to 12 months [12]. Calhoun’s study relied
on patient reported utilization and standard fee data whereas
data here are actual reimbursements, which may, in addition
tothediﬀerenceinlengthoffollowup,explainthediﬀerences
in estimates. Calhoun also analyzed indirect costs based
on national labor force, employment, and earnings data,
including patient workloss, caregiver workloss, and paid
caregiver costs. Calhoun found indirect costs were $4,220,
with 67% of that due to caregiver workloss. Patient workloss
costs were $620 per patient per episode compared with our
ﬁndings of $642 per patient per year in excess medically
related absenteeism costs. Though Calhoun did not include
disability costs, this study found CAPN patients had mean
excess per patient per year disability costs of $1,614. While
the workloss ﬁndings were not statistically signiﬁcant, this
may be due to the small sample size. It is important to
note that the workloss cost estimates reported in this study
may diﬀer from actual employer costs depending on the
employer’s paid time oﬀ policies.
Healthcare costs and resource use were calculated for
diabetic CAPN patients as a secondary analysis as literature
suggests that diabetes may exacerbate the risk and severity
of CAPN. With the prevalence of diabetes increasing, it is
important to assess how diabetic CAPN patients may diﬀer
from controls and nondiabetic CAPN patients. The results
demonstrated that diabetes may, indeed, be associated with
increased cost in patients with CAPN, as excess costs of
diabetic CAPN patients were 25% higher than for nondi-
abetic CAPN patients. However, the comparison between
diabetic and nondiabetic CAPN patients was not statistically
signiﬁcant, perhaps due to the small sample of diabetic
CAPN patients. In addition, although diabetic cases were
balanced with their controls in terms of costs and resource
use, a higher proportion of cases had metastatic cancer and
the CCI of cases was signiﬁcantly higher than controls. Both
these factors could impact the excess cost ﬁndings.
This study is limited by the lack of clinical measures,
which is common to research that uses claims data. While
propensity score matching was used to adjust for many
baseline group diﬀerences, the possibility exists of other
confounding factors not available in this database. Moreover,
because CAPN does not have a speciﬁc diagnosis code and is
not consistently recorded in claims data, there are challenges
in identifying the condition. Physicians may not report
CAPN unless the impairment is severe enough to aﬀect a
patient’s activities of daily living or warrant alterations to
cancer treatment [1]. Thus, this study may include more
severe cases of CAPN and may have under identiﬁed CAPN
patients. The algorithm used for identifying CAPN in this
study has not been validated. It is possible that the PN
identiﬁed was due to other causes. Another study limitation
isthatduetodataavailability,casesandcontrolsarematched
using only 3 months of baseline data and information on
cancer stage beyond metastatic/nonmetastatic is not avail-
able. A longer baseline period using a larger database with
clinical information on cancer stage may allow for additional
controls. The lack of restrictions on the length of continuous
eligibility following index date is another possible limitation.
This limitation could potentially lead to censoring of costs if
a patient’s plan were to have withdrawn from the database
while the patient was continuing to incur costs; however, no
such instances occurred in the study and the average length
of followup for patients in the study is 11.1 months. Finally,
smallsamplesizes,particularlyintheheadandneck,ovarian,
workloss cost, and diabetic analyses, limited both the types
of comparisons as well as the robustness of the statistical
inferences. Though this study reports directional diﬀerences
in workloss outcome measures, no signiﬁcant diﬀerences
were found, potentially due to the small sample size.
5. Conclusion
CAPN patients are associated with signiﬁcantly higher
healthcare costs and resource use in patients with breast,
ovarian, head/neck, or NSCLC. The excess healthcare cost
of CAPN is underestimated when only the cost for med-
ical or pharmacy claims directly for CAPN is considered.
Improvements in clinical assessments and treatments for
CAPN would be useful for patients and payors.
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